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INTRODUCTION
The pre-administration of the anti-inflammatory drugs
dexamethasone (DEX) and cortisone acetate reduces toxicity
and enhances efficacy of anticancer agents in murine models
and in human clinical trials (1–5). We previously reported on
the formulation of the lipophilic dexamethasone palmitate
ester (DEX-P) in nanoparticles (NPs) employing a micro-
emulsion template engineering technique to achieve tumor-
specific delivery of dexamethasone (6). The nanoparticles
exhibited significantly enhanced stealth properties as indicated
by reduced macrophage uptake and decreased adsorption of
opsonin proteins in in vitro assays (6). Unexpectedly, prelimi-
nary biodistribution studies of NPs containing [3H]-DEX-P in
tumor-bearing mice showed that the radiolabel was cleared
from the circulation rapidly and exhibited high liver uptake. Our
previous in vitro release studies demonstrated that rapid release
of the radiolabel from the NPs was observed when 10% mouse
plasma was used as the medium, while nominal release was
observed in phosphate-buffered saline (PBS) buffer (6).
Esterolysis of NP-associated DEX-P was presumed to be the
main cause for the rapid drug release in plasma, as most of the
released radioactivity was in the form of DEX and not DEX-P.
High degradation rates of ester prodrugs in rodent plasma has
been attributed to increased esterase activity, while only
minimal degradation in human plasma has been observed (7–
9). Based on our observation of the release of [3H]-DEX from
NPs in mouse plasma, we studied the release of DEX from
nanoparticles in various plasma sources as a guide for the design
of future in vivo experiments.
MATERIALS AND METHODS
Materials
Tritiated dexamethasone-([6,7-3H(N)]; specific activity=
35–50 Ci/mmol) was purchased from American Radiolabeled
Chemicals (Saint Louis, MO, USA). Bis(p-nitrophenyl)
phosphate (BNPP) was purchased from Sigma-Aldrich (St.
Louis, MO, USA). Mouse and human plasma containing Na
heparin were purchased from Innovative Research (Novi, MI,
USA). Plasma from nu/nu mice and Sprague–Dawley rats were
obtained from animals housed at the University of Kentucky
and from carboxylesterase-deficient mice (Es1e(−/−)/SCID)
maintained at St. Jude Children’s Research Hospital.
Preparation of Radiolabeled Nanoparticles
The procedure to prepare radiolabeled DEX-P and the
method to incorporate it into solid lipid nanoparticles by the
nanotemplate engineering approach have been previously
described (6). Briefly, [3H]-DEX-P was synthesized by the
reaction of [3H]-DEX and palmitoyl chloride. Nanoparticles
were derived from a microemulsion comprising stearyl alcohol
(1.6 mg/mL), [3H]-DEX-P (20% of the weight of the stearyl
alcohol), polysorbate 60 (0.4mg/mL), Brij78® (2.8mg/mL), and
PEG6000 MS (3 mg/mL) that was prepared by adding warm
PBS buffer (pH 7.4, 70°C) to themeltedmixture of oil, drug, and
surfactants. After stirring in a 70°C water bath for 1 h, the warm
microemulsion was cooled to 25°C, resulting in the formation of
nanoparticles. Nanoparticle suspensions were diluted 1:30 (v/v)
with filtered PBS buffer (0.22 μm filter, Nalgene International)
and then incubated at 37°C for 0–20 h. Particle size distributions
were measured at 37°C by photon correlation spectroscopy
using a Coulter N4 Plus Submicron Particle Sizer (Beckman
Coulter Corporation, Miami, FL, USA), n=3.
Release of Drug from Nanoparticles in Various Media
The media used in the in vitro [3H] release study included
PBS buffer, plasma from nu/nu and carboxylesterase-deficient
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mice, rats, and humans. Human tumor (A549) homogenate
grown in nu/nu mice and A549 cell lysate from cells grown in
vitro were also used. Heat-denatured plasma (70°C for 30 min)
or BNPP-treated plasma were used as controls. A suspension
of NPs containing [3H]-DEX-Pwas added to 10%media (diluted
with PBS buffer) at a ratio of 1:14 (v/v) and incubated at 37°C for
up to 24 h. Ultrafiltration (Millipore Ultracel YM-100) was used
to separate the particles from the medium, and the radioactivity
that was released into the filtrate was quantified by liquid
scintillation counting. Thin-layer chromatography (TLC) was
used to quantify the amount of [3H]-DEX-P and [3H]-DEX that
had been released into the medium.
Statistical Analysis
Data are presented as mean±standard deviation. Groups
were compared using analysis of variance, one-way or two-
way tests as appropriate, with SigmaStat 3.11 software
(Systat, San Jose, CA, USA). Differences were considered
statistically significant when P<0.05, and the Holm–Sidak
method was used to perform pair-wise multiple comparisons
on significant effects and interactions.
RESULTS AND DISCUSSION
The size stability of [3H]-DEX-P loaded NPs was initially
assessed in PBS buffer at 37°C to rule out the release of drug
from the NPs due to particle degradation. As seen in Fig. 1, the
size of the particles remained constant during the first 3 h in
which NP particle size was measured. A slight but not
statistically significant increase in the average particle size
from 125.7 (±16.3) nm to 164.7 (±24.3) nm was observed after
20 h of incubation at 37°C.At all times, the suspension remained
clear with no evidence of particle aggregation or flocculation.
These studies confirmed our previous results in which we used
[14C]-stearyl alcohol, a primary matrix component, to
demonstrate that the particles remained intact (6).
Here, initial release studies showed that only 7.3±0.4%
release of [3H] from NPs was detected after 7 days when PBS
buffer was used as the release media. In contrast, when the
radiolabeled NPs were suspended in 10% mouse plasma, a
burst release (5.0±0.3%) of the radiolabel was observed, and
after 3 h, approximately 55.7±0.4% of the radiolabel was
detected in the filtrate. TLC analysis demonstrated that most
of the radioactivity (3H) in the retentate (i.e., in the NPs) was
present as intact DEX-P, while analysis of the filtrates
revealed that 100% of the radioactivity was present as DEX
indicating that de-esterification of DEX-P had occurred.
The palmitate ester ofDEX is nearly insoluble in water and
has been reported to be an amphipathic molecule that can insert
into phospholipid monolayers (10). As such, during the
preparation of the NPs, DEX-P is expected to align itself in
the microemulsion precursor with the DEX group directed
toward the aqueous phase and the hydrophobic palmitate chain
embedded in the oil phase. After cooling to form the NPs, this
orientation may allow plasma esterases easy access to the ester
bond of DEX-P resulting in the release of DEX, which has a
water solubility of 100 μg/mL, from the nanoparticle matrix.
We anticipated that the addition of polyethylene glycol
(PEG) derivatives to the NP formulations might impede
degradation of DEX-P by shielding the molecule from
exposure to enzymes. While increased addition of PEG6000
MS to NP formulations was able to reduce macrophage
uptake in vitro (6), the addition of this PEGylating agent and
others, including DSPE-PEG5000, did not change the release
profile of radioactivity when the [3H]-DEX-NPs were incubated
in 10%mouse plasma. The results showed that incorporation of
amphipathic esters into PEGylated nanoparticles may not
necessarily protect the compound from enzymatic degradation.
This has implications for studies conducted in mice that employ
various nanoparticle carriers containing esters, including
PEGylating agents bound to nanocarriers via ester linkages.
Results from preliminary in vivo studies revealed a
difference in the disposition of the radiolabeled drug in
mouse and rat. Thus, additional studies measuring the release
of radioactivity from [3H]-DEX-NPs in 10% heparinized
plasma from different species were conducted (Fig. 2). The
time-dependent release over 24 h is depicted in the figure
with denatured 10% mouse plasma as the control, showing
negligible release (2.8±0.1%) after 24 h. Following 24 h of
Fig. 1. [3H]-DEX-P nanoparticle size following incubation in PBS at
37°C. Each value represents the mean±SD (n=3)
Fig. 2. Release of [3H] from nanoparticles containing [3H]-DEX-P in
10% plasma from different sources and in 10% human tumor
xenograft homogenate. Each value represents the mean±SD (n=3)
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incubation, extensive release was observed fromNPs suspended
in nu/nu mouse plasma (97.7±3.2%) and rat plasma (47.2±
0.2%). In contrast, much lower release (22.0±1.0%) was
observed when the NPs were suspended in plasma obtained
from carboxylesterase-deficient mice (Es1e(−/−)/SCID).
Multiple comparisons versus the denatured plasma control
group were done using the Holm–Sidak method. The release
of the radiolabel increased with time in mouse, rat, and Es1e
(−/−)/SCID mouse plasma and was significantly different from
that of the control group (P<0.001). The role of esterases in the
release of DEX from the nanoparticles was confirmed as mouse
plasma containing the esterase inhibitor BNPP (1 mM) showed
low release (4.1±0.3%). Interestingly, nominal release (1.6±
0.1%) was observed from NPs suspended in human plasma,
showing no significant difference from the denatured plasma
control group. NPs incubated in a human tumor homogenate
showed a much greater extent of release than human plasma.
Subsequently, to confirm that DEX-P hydrolysis in human
tumor xenograft homogenate was not the result of any residual
mouse plasma activity, we prepared cell lysates from the same
tumor type (A549) grown in vitro. Extensive release was also
observed in 10% tumor cell lysate (88.9±5.5%) after 24 h.
Carboxylesterase and butyrylcholinesterase are two major
esterases known to degrade prodrugs (11), and their activities in
a variety of animal species have been thoroughly characterized
(9). The release of radiolabeled drug from the NPs in 10%
plasma from a carboxylesterase-deficient mouse was significant-
ly lower than that observed in mouse and rat plasma, although
an increase in the release of the radiolabel was observed with
time. It has been reported that liver homogenates have greater
esterase-specific activities compared to plasma in both rodents
and humans (9). In our study, minimal drug release from the
NPs was observed in human plasma, but DEX-P might be de-
esterified in human liver because of its high esterase activity.
Previous studies by us and others on opsonin protein adsorption
and macrophage uptake suggest that PEGylated nanoparticles
can avoid rapid uptake by the reticuloendothelial system
leading to increased residence times in the circulation (6,12).
The rapid release of the radiolabel in human tumor homogenate
indicated the potential of esterases to serve as a trigger to
release DEX in tumors after passive accumulation of DEX-P
NPs via the enhanced permeability and retention (EPR) effect.
CONCLUSION
Studies with nanoparticles containing amphipathic esters
should be conducted with caution in rodents. Our studies clearly
demonstrate that their esterase-rich plasma will alter biodistri-
bution. This limitation may be overcome, to some extent, by
using a carboxylesterase-deficient mousemodel. In humans, it is
speculated that PEGylated dexamethasone palmitate delivered
in a solid lipid nanoparticle will not be de-esterified in plasma,
but rapid de-esterification to dexamethasone will occur in the
tumor after accumulation via the EPR effect. The released
dexamethasone can then act to reduce interstitial hydrostatic
pressure resulting in the enhancement of the uptake of
systemically administered chemotherapeutic agents.
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